Alerts will be sent to your verified email
Verify Email
SYNCOMF
|
Syncom Formulations
|
Jagsonpal Pharma
|
Beta Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
9.79 % | 16.01 % | 22.74 % |
|
5yr average Equity Multiplier
|
1.41 | 1.27 | 1.82 |
|
5yr Average Asset Turnover Ratio
|
0.81 | 1.09 | 1.03 |
|
5yr Avg Net Profit Margin
|
8.78 % | 12.08 % | 12.23 % |
|
Price to Book
|
3.77 | 5.3 | 8.35 |
|
P/E
|
22.63 | 21.65 | 38.81 |
|
5yr Avg Cash Conversion Cycle
|
61.57 Days | 2.39 Days | 7.75 Days |
|
Inventory Days
|
27.32 Days | 37.29 Days | 46.07 Days |
|
Days Receivable
|
82.75 Days | 15.63 Days | 91.57 Days |
|
Days Payable
|
79.41 Days | 59.94 Days | 119.03 Days |
|
5yr Average Interest Coverage Ratio
|
31.44 | 66.99 | 14.42 |
|
5yr Avg ROCE
|
13.63 % | 18.99 % | 27.84 % |
|
5yr Avg Operating Profit Margin
|
9.97 % | 13.23 % | 21.76 % |
|
5 yr average Debt to Equity
|
0.19 | 0.01 | 0.29 |
|
5yr CAGR Net Profit
|
36.24 % | 26.54 % | 29.34 % |
|
5yr Average Return on Assets
|
7.11 % | 12.71 % | 12.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
50.57 % | 67.54 % | 66.73 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -1.18 % | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Syncom Formulations
|
Jagsonpal Pharma
|
Beta Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Raw Material Break-Up
|
Raw Material Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|